☆ 4.5 Article

Proactive therapy: New perspectives for long-term topical treatment of psoriasis

DERMATOLOGIC THERAPY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Dermatology

Long-term topical management of psoriasis: the road ahead

Siegfried Segaert et al.

Summary: This article reviews the unmet needs in long-term management of psoriasis, suggesting that topical therapies could be the best treatment option in certain phases of the chronic disease. It calls for clinical alignment on terminology, recommending 'long-term management' as the most appropriate term, and provides recommendations for the implementation of topicals as part of long-term management strategies.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland

Rauno J. Harvima et al.

Summary: The study found that proactive management with Cal/BD foam showed consistent clinical benefits compared to reactive management on all response criteria, and resulted in significantly lower cost-per-responder for mPASI 75, mPASI <= 2, and DLQI <= 1 criteria. The analysis demonstrated the cost-effectiveness and clinical benefits of proactive management of plaque psoriasis with Cal/BD foam in the Finnish healthcare setting.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG

A. Jalili et al.

Summary: This study analyzed the impact of long-term use of fixed-dose combination calcipotriene and betamethasone dipropionate foam on health-related quality of life and symptom severity in patients with psoriasis. Results showed that patients in the proactive management arm had significantly better DLQI and PSI scores compared to the reactive management arm. In addition, in terms of PROs, patients with baseline flare had worse outcomes than those with relapse or in remission.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

添加到收藏夹

Article Dermatology

Calcipotriol/Betamethasone Dipropionate Foam Inhibits Th17 Cytokine Secretion and Improves Epidermal Barrier Markers in a Human Th17 Skin Inflammation Model

Paola Lovato et al.

Summary: In this study, the effects of a fixed-dose combination of Cal/BD foam and CP cream on Th17 cytokine secretion and epidermal differentiation were investigated. Cal/BD foam significantly inhibited Th17 cytokine secretion and improved the expression of epidermal differentiation markers, while CP cream reduced Th17 cytokine levels to a lesser extent and did not improve epidermal differentiation markers.

DERMATOLOGY AND THERAPY (2021)

添加到收藏夹

Article Dermatology

Early efficacy and safety data with fixed-dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency

Y. Tada et al.

Summary: This article discusses the potency and absorption of fixed-dose combination Cal/BD foam, as well as the positive early efficacy and safety data associated with its utilization in the treatment of psoriasis vulgaris. Early data indicate that Cal/BD foam forms a supersaturated solution on the skin, increasing the penetration and bioavailability of Cal and BD, resulting in improved efficacy outcomes without negatively affecting safety outcomes.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immunological Memory in Imiquimod-Induced Murine Model of Psoriasiform Dermatitis

Kevin Fenix et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Article Dermatology

Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)

Mark Lebwohl et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

添加到收藏夹

Letter Dermatology

Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis

Mark G. Lebwohl et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

添加到收藏夹

Article Dermatology

A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/ betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP)

K. Reich et al.

BRITISH JOURNAL OF DERMATOLOGY (2017)

添加到收藏夹

Article Dermatology

Proactive treatment with calcipotriol reduces recurrence of plaque psoriasis

Kotaro Ito et al.

JOURNAL OF DERMATOLOGY (2016)

添加到收藏夹

Article Dermatology

Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study

J. Lambert et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)

添加到收藏夹

Review Dermatology

Topical long-term therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice

Matthias Augustin et al.

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2014)

添加到收藏夹

Article Dermatology

Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients

Rosita Saraceno et al.

JOURNAL OF DERMATOLOGICAL TREATMENT (2014)

添加到收藏夹

Article Dermatology

A Study of the Safety and Efficacy of Calcipotriol and Betamethasone Dipropionate Scalp Formulation in the Long-Term Management of Scalp Psoriasis

T. A. Luger et al.

DERMATOLOGY (2008)

添加到收藏夹

Article Dermatology

A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet®/Daivobet®/Taclonex®) in the treatment of psoriasis vulgaris

K. Kragballe et al.

BRITISH JOURNAL OF DERMATOLOGY (2006)

添加到收藏夹

Article Dermatology

Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet (R)/Dovobet (R)/Taclonex (R)) in the treatment of psoriasis vulgaris

K. Kragballe et al.

DERMATOLOGY (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.